Jeremy Levin, who was pushed from his CEO position at Teva Pharmaceutical in late 2013 after a disagreement with the board, has announced his intentions to serve as CEO for a U.S. biotech startup focused on brain diseases.
NY-based Ovid Therapeutics will license a drug for two rare brain diseases from Copenhagen-based H. Lundbeck A/S.
“Expect us to do more licensing agreements focused initially on orphan and rare diseases,” Levin said. “We also have our own in-house research and development, and as we grow, we will acquire outright products that are of value.”
Read the Bloomberg release